Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear methodological standards, and without crushing noncommercial research, could make trials safer, faster, cheaper, and more reliable, without sacrificing rigor.
For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance.
Medical students, residents, and fellows are not waiting for formal guidance on artificial intelligence before putting it to use.
Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a contractor gets it wrong, there should be a clear and rapid way to stop the harm to patients, their relationship with their doctor and the doctor’s practice.
Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation
The policy conversation needs to shift from just deprescribing alone to building the clinical infrastructure that delivers consistent, high-quality behavioral health care.
Rural Health Transformation Program funding gives states broad flexibility and may help address longstanding access gaps.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
The July 1 changes are being framed as student loan policy. But they raise a larger question about what kind of labor, and whose labor, America is willing to invest in.
For years the healthcare system has relied on the slow machinery of research — and that system is failing the people it was built for. It was designed for a world that operated with an abundance of caution and lacked the modern tools of today. That world no longer exists.
This is not an abstract discussion. It is about sustaining the organizations, employees, and communities that depend on us. If we fail to account for how these policies interact in the real world, we risk weakening the very system we are trying to improve.
Today’s adjustment offers insight into what the next phase of the program is focusing on and will subsequently reward, and why this moment matters, especially for newer and regional plans.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
At the center of this issue is a simple question: should the entities responsible for managing prescription drug benefits also own the pharmacies that profit from those decisions?
The message to the industry is clear: If your business model is optimized only for FFS, you are the legacy. The future of healthcare belongs to those who can trade hours spent for improved patient lives.
Healthcare often expects consumers to contort themselves around processes that were never built with them in mind — and that’s where the trust issue begins. With the looming arrival of HR1, how to fix it.
The most successful and high-performing health systems will approach TEAM not as a regulatory burden, but as a catalyst for transformation. They will use this moment to build the operating model, processes, workflows, and culture that position their health system for long-term success in value-based care.
While other areas of healthcare have been star-struck by sophisticated AI and massive infrastructure investments, safety net entities have found that the answer is much simpler. Better managing chronic conditions across populations simply requires the right connection at the right time.